SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is at the center of intense debate following a recent test flight where successful satellite deployment and re-entry maneuvers were overshadowed by a booster landing challenge. The community remains deeply divided, with bulls pointing to the company's long-term space exploration roadmap while bears highlight the upcoming expiration of IPO lock-up shares and the stock's lack of consistent profitability.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members hotly debate the company's exposure to geopolitical instability, trade policies, and recent administrative decisions. The conversation is characterized by a stark divide between vocal supporters rallying behind the platform's leadership and critics pointing to the company's volatility and its connection to broader market concerns.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is currently experiencing heightened volatility as investors debate the impact of broader defense sector trends and recent index rebalancing on its high-growth potential. Community discussion is heavily focused on the company's long-term capability to scale silicon-anode production for mission-critical drone applications while simultaneously navigating short-term price swings and market skepticism.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber Technologies is seeing intense community debate following reports that Waymo is exploring an independent path for its robotaxi operations, leading investors to weigh the impact on Uber's autonomous strategy against the company's strong cash flow and platform scale. Despite concerns over potential competition, many are focused on the stock's valuation and long-term potential as an essential aggregator for rides and delivery.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is experiencing intense volatility and downward pressure as investors rotate out of recent high-beta runners, with the community actively debating whether the current sell-off is a buying opportunity or a deeper structural decline. While long-term bulls point to Enphase's potential pivot into AI data center infrastructure through its solid-state transformer technology, many market participants remain frustrated by the stock's sharp reversals and ongoing uncertainty regarding the broader solar sector's policy environment.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to significant selling pressure and volatility that has pushed the stock to new 52-week lows, leaving retail investors sharply divided between those viewing the current valuation as a generational buying opportunity and those fearing a long-term decline. While community discussions remain focused on institutional short interest and market sentiment, bulls are closely tracking potential buybacks and upcoming earnings for a catalyst to drive a reversal.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is seeing significant volatility ahead of its upcoming earnings, driven by intense debate over its supply chain and recent permit delays for major data center projects. Despite a recent pullback, the community remains actively engaged, with many investors weighing the long-term potential of its fuel cell technology against concerns from short-seller reports and institutional positioning.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

The Vanguard Total Stock Market ETF (VTI) remains a primary focal point for investors seeking broad market exposure as a defensive "set it and forget it" strategy during periods of ongoing geopolitical and macroeconomic volatility. Community sentiment centers on the ETF as a core portfolio anchor, with many users prioritizing long-term accumulation and discipline over the risks associated with individual stock picking or market timing.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is gaining attention as investors debate its transition from a struggling cell-engineering company to a specialized infrastructure provider focused on autonomous lab automation and AI-driven biological design. While some community members remain skeptical due to past revenue volatility and aggressive cash burn, others are tracking its potential as a strategic domestic partner amid increasing geopolitical scrutiny of foreign biotech and broader government efforts to secure national bio-infrastructure.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to intensifying speculation regarding its soquelitinib drug candidate and potential strategic partnerships or M&A activity. The community is actively debating the stock's valuation, fueled by heavy short interest and high-profile analyst coverage that contrasts sharply with skepticism over the company's long-term commercialization path.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?

Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy

Equity

Artiva announced a $300 million public offering to support the development of its autoimmune disease therapies, but at a 9% discount per share compared to Thursday’s closing price.

Artiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise

(RTTNews) - Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants...

Artiva Biotherapeutics (NASDAQ:ARTV) Earns "Buy" Rating from Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Monday...

Artiva Biotherapeutics (NASDAQ:ARTV) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are covering the stock, Marketbeat.com reports. One...

Artiva Biotherapeutics (NASDAQ:ARTV) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Monday...

Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham

Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said...

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.63	--	--	N/A
Q1 '26	-$0.87	-$0.95	-9.20%	MISSED
Q4 '25	-$0.85	-$0.85	-0.36%	MISSED
Q3 '25	-$0.87	-$0.88	-1.34%	MISSED
Q2 '25	-$0.81	-$0.87	-7.92%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARTVArtiva Biotherapeutics Inc

Latest Earnings Results: Q1 '26

Historical Earnings

Latest ARTV News